Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

CAMBRIDGE, Mass., Sept. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9, 2009 at 10:55 a.m. ET at the Four Seasons Hotel in Boston, Massachusetts, and at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September( )14, 2009 at 3:55 p.m. ET at the Grand Hyatt Hotel, New York.

The live and archived webcasts of the presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the events to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
2. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
3. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
4. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
5. Idenix Pharmaceuticals Reports First Quarter Financial Results
6. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
7. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
8. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
10. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
11. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... , ... July 13, 2017 , ... ... accreditation in Specialty Pharmacy. URAC is the independent leader in promoting healthcare quality ... a comprehensive commitment to quality care, improved processes and better patient outcomes. ...
(Date:7/13/2017)... ... July 13, 2017 , ... FireflySci Inc. started ... Blast forward seven years and now they are home to a tremendous line ... wavelength accuracy, and resolution testing. , One mega advantage that FireflySci ...
(Date:7/13/2017)... ... July 13, 2017 , ... After 11 years ... Science Center, Christopher Laing, MRCVS, Ph.D. has been tapped to lead the effort ... will become the first Executive Director at the newly formed Capital City Innovation ...
(Date:7/13/2017)... , ... July 13, 2017 , ... Microscan , ... solutions for life sciences, will demonstrate advancements of the MicroHAWK platform for barcode reading ... from Booth #4456 at the AACC Clinical Lab Expo, taking place on August 1–3 ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):